Ranbaxy, GSK Settle Patent Dispute Over Imitrex (India)
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories and GlaxoSmithKline settled a patent dispute over Ranbaxy's generic version of Imitrex (sumatriptan) for treating migraines. The agreement calls for India's Ranbaxy to be able to sell its generic in the U.S. after next December. Other parts of the settlement were not disclosed, but Ranbaxy estimates annual Imitrex sales at $985 million. (Click here for more